The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, today announced the publication of long ...
WASHINGTON & REDWOOD CITY, Calif.--(BUSINESS WIRE)--Pulmonx®, Inc. today announced the results of two multi-center, randomized clinical trials showing clinically meaningful improvements in lung ...
The Zephyr valve is a device that can improve breathing in people with emphysema, one of the two most common types of chronic obstructive pulmonary disease (COPD). The valve received approval by the ...
VIENNA — Bronchoscopic lung volume reduction (BLVR) was associated with sustained improvements in adults with severe emphysema over a 5-year period, based on data from 190 individuals. The LIBERATE ...
The US Food and Drug Administration (FDA) has approved the Zephyr Endobronchial Valve (Pulmonx Corp) to treat breathing difficulty associated with severe emphysema. "Treatment options are limited for ...
Daily, people all around West Michigan and the world feel like they are suffocating. It's not because of the stress daily life can bring, but because of a condition known as COPD with Emphysema. The ...
The Zephyr Valve Helps COPD/Emphysema Patients Breathe Easier Without the Risk of Major Surgery 1 REDWOOD CITY, Calif., Nov. 30, 2020 (GLOBE NEWSWIRE) -- As part of COPD Awareness Month, Pulmonx ...
Positive Coverage Policy from Health Care Service Corporation (HCSC) Covers Blue Cross Blue Shield Members in Illinois, Montana, New Mexico, Oklahoma and Texas REDWOOD CITY, Calif., Nov. 02, 2020 ...
New Data Presented at ATS 2021 International Conference Shows Positive, Sustained Benefits to Patients Treated with this First Minimally Invasive, Non-drug Treatment Option REDWOOD CITY, Calif., May ...
REDWOOD CITY, Calif., May 17, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, announced that key long ...